Signaling Mechanisms of Stem Cell Therapy for Intervertebral Disc Degeneration
- PMID: 37760908
- PMCID: PMC10525468
- DOI: 10.3390/biomedicines11092467
Signaling Mechanisms of Stem Cell Therapy for Intervertebral Disc Degeneration
Abstract
Low back pain is the leading cause of disability worldwide. Intervertebral disc degeneration (IDD) is the primary clinical risk factor for low back pain and the pathological cause of disc herniation, spinal stenosis, and spinal deformity. A possible approach to improve the clinical practice of IDD-related diseases is to incorporate biomarkers in diagnosis, therapeutic intervention, and prognosis prediction. IDD pathology is still unclear. Regarding molecular mechanisms, cellular signaling pathways constitute a complex network of signaling pathways that coordinate cell survival, proliferation, differentiation, and metabolism. Recently, stem cells have shown great potential in clinical applications for IDD. In this review, the roles of multiple signaling pathways and related stem cell treatment in IDD are summarized and described. This review seeks to investigate the mechanisms and potential therapeutic effects of stem cells in IDD and identify new therapeutic treatments for IDD-related disorders.
Keywords: intervertebral disc; signaling pathway; stem cell treatment; tissue degeneration.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Oxidative stress in intervertebral disc degeneration: Molecular mechanisms, pathogenesis and treatment.Cell Prolif. 2023 Sep;56(9):e13448. doi: 10.1111/cpr.13448. Epub 2023 Mar 13. Cell Prolif. 2023. PMID: 36915968 Free PMC article. Review.
-
Unraveling the mechanisms of intervertebral disc degeneration: an exploration of the p38 MAPK signaling pathway.Front Cell Dev Biol. 2024 Jan 19;11:1324561. doi: 10.3389/fcell.2023.1324561. eCollection 2023. Front Cell Dev Biol. 2024. PMID: 38313000 Free PMC article. Review.
-
Targeting Oxidative Stress and Inflammation in Intervertebral Disc Degeneration: Therapeutic Perspectives of Phytochemicals.Front Pharmacol. 2022 Jul 12;13:956355. doi: 10.3389/fphar.2022.956355. eCollection 2022. Front Pharmacol. 2022. PMID: 35903342 Free PMC article. Review.
-
Treatment of Intervertebral Disc Degeneration.Orthop Surg. 2022 Jul;14(7):1271-1280. doi: 10.1111/os.13254. Epub 2022 Apr 29. Orthop Surg. 2022. PMID: 35486489 Free PMC article. Review.
-
IL-1β-mediated inflammatory responses in intervertebral disc degeneration: Mechanisms, signaling pathways, and therapeutic potential.Heliyon. 2023 Sep 7;9(9):e19951. doi: 10.1016/j.heliyon.2023.e19951. eCollection 2023 Sep. Heliyon. 2023. PMID: 37809657 Free PMC article. Review.
Cited by
-
Stem cell therapy for intervertebral disc degeneration: Clinical progress with exosomes and gene vectors.World J Stem Cells. 2025 Apr 26;17(4):102945. doi: 10.4252/wjsc.v17.i4.102945. World J Stem Cells. 2025. PMID: 40308883 Free PMC article. Review.
-
Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration.Front Pharmacol. 2025 Apr 28;16:1583635. doi: 10.3389/fphar.2025.1583635. eCollection 2025. Front Pharmacol. 2025. PMID: 40356987 Free PMC article.
-
Hypoxia-Preconditioned BMSC-Derived Exosomes Induce Mitophagy via the BNIP3-ANAX2 Axis to Alleviate Intervertebral Disc Degeneration.Adv Sci (Weinh). 2024 Sep;11(34):e2404275. doi: 10.1002/advs.202404275. Epub 2024 Jul 8. Adv Sci (Weinh). 2024. PMID: 38973294 Free PMC article.
-
Pluripotent Stem Cells: Recent Advances and Emerging Trends.Biomedicines. 2025 Mar 21;13(4):765. doi: 10.3390/biomedicines13040765. Biomedicines. 2025. PMID: 40299329 Free PMC article.
References
-
- Vos T., Allen C., Arora M., Barber R.M., Bhutta Z.A., Brown A., Carter A., Casey D.C., Charlson F.J., Chen A.Z., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. doi: 10.1016/S0140-6736(16)31678-6. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources